Urinary Tract Infection (UTI) is caused when bacteria enters the urethra and infects the urinary bladder, causing severe health issues. UTI infections are common health problems in females than in males with biologic factors accounting as the major cause. Antibiotics are usually the first line of treatment prescribed by doctors for urinary tract infections. According to the site of manifestation by the microbe, infections are classified as cystitis (bladder), urethritis (urethra), prostatitis (prostate) or pyelonephritis (kidney). Painful and increased frequency of urination, excessive and involuntary passing of urine at night are the common symptoms associated with UTI. Hospitalized patients using urinary catheters are at a higher risk for developing UTI.

Increasing prevalence of recurring urinary infections is expected to boost growth of the urinary tract infection treatment market

Rise in chronic kidney diseases and increasing use of urinary catheterization is leading to development of urinary infections and this is expected to be major growth drivers for urinary tract infection market. According to the Centers of Disease Control and Prevention, 2016, UTIs are the most common bacterial infections globally, affecting 150 million people every year. Furthermore, about 10 in 25 women and 3 in 25 men are estimated to have symptoms of at least one UTI during their lifetime. According to the study by Sultan Qaboos University Medical Journal, 2013, around 50–60% of women report at least one UTI in their lifetime, and one in three will have at least one symptomatic UTI necessitating antibiotic treatment by age 24. Also, patients with diabetes have a higher frequency of UTIs, due to the presence of long-term complications of diabetes such as neuropathy. According to the American Diabetes Association, in 2017, 9.4% of the people diagnosed with type 2 diabetes had a UTI compared to only 5.7% of people without diabetes.

Approval of combination products for improving indications of existing drugs and to combat multi-drug resistant bacteria are some key factors positively affecting market growth. For instance, in 2015, FDA approved Avycaz (ceftazidime and avibactam) for complicated abdominal and urinary tract infections in combination with metronidazole that has limited or no alternative treatment options.

Market Taxonomy:

The global urinary tract infection treatment market is segmented on the basis of drug type, indications, distribution channel, and geography.

On the basis of drug type, the global urinary tract infection treatment market is segmented into:

  • Nitrofurans
  • Sulphonamides
  • Quinolones
  • Azoles and Amphotericin B
  • Aminoglycoside antibiotics
  • Tetracycline
  • Others

On the basis of indication, the global urinary tract infection treatment market is segmented into:

  • Complicated UTI
  • Uncomplicated UTI
  • Recurring Complicated UTI

On the basis of distribution channel, the global urinary tract infection market is segmented into:

  • Hospital Pharmacies
  • e-Pharmacies
  • Retail Pharmacies

Rising catheter associated urinary infections is expected to fuel growth of the urinary tract infection treatment market in North America

Regional segmentation of the urinary tract infection treatment market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to dominate the global market owing to higher prevalence of neurogenic bladder infections, catheter associated infections and increased research and development spending on new drugs. According to the Agency of Healthcare Research and Quality — one of 12 Agencies within the United States Department of Health and Human Services —2016, around 250,000 catheter-associated urinary tract infections are reported in hospitals each year, costing about US $ 250 million in the U.S. Moreover, in 2016, the Agency for Healthcare Research and Quality (AHRQ), along with the Health Research and Educational Trust launched a nationwide effort to implement the Comprehensive Unit-based Safety Program (CUSP) to reduce catheter-associated UTIs in the U.S. hospitals. Asia Pacific is expected to exhibit fastest growth in the market owing to increasing prevalence of diabetes, and government initiatives to invest in research and development in emerging economies such as China and India. According to the Asian Diabetes Prevention Initiative, 2013, an estimated 113.9 million adults in China, and 65.1 million adults in India have diabetes. By 2030, China and India combined will have almost half a billion diabetics.

Strategic collaborations is the strategy adopted by key players in the market to enhance its presence and for new drug development

Strategy of leading players is to achieve growth through mergers & acquisitions and collaborations. In 2016, GlaxoSmithKline and Fimbrion Therapeutics, Inc., entered into a collaboration, which is focused on preclinical development of mannose-containing small molecule compounds called mannosides for the treatment and prevention of urinary tract infections.

Key players operating in the urinary tract infection treatment market include Cipla Ltd., Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., Novartis AG AstraZeneca Plc, and Roche Ltd.